Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 30.2% in December

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 74,100 shares, a growth of 30.2% from the November 30th total of 56,900 shares. Based on an average daily volume of 44,100 shares, the short-interest ratio is currently 1.7 days. Approximately 0.6% of the company’s shares are sold short.

Akari Therapeutics Stock Up 2.3 %

Shares of NASDAQ AKTX traded up $0.02 during mid-day trading on Monday, hitting $0.99. The stock had a trading volume of 53,740 shares, compared to its average volume of 25,176. The business has a 50 day moving average price of $1.63 and a two-hundred day moving average price of $2.72. Akari Therapeutics has a 1 year low of $0.90 and a 1 year high of $4.40.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Akari Therapeutics in a report on Saturday. They set a “sell” rating for the company.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.